MB-202

N/A

Report date: 2022/01/05 15:24:33

Base Information

Drug NameMB-202
Drug Alias NameMB-202
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsMesothelin
Therapy Area/IndicationsOvarian NeoplasmsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Monroe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Monroe Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A